Flat rate shipping β€” $9 dry goods Β· $13 chilled gel 🌿

science safety

Carrageenan vs. Poligeenan: The Molecular Weight Distinction

Food-grade carrageenan and poligeenan are distinct substances separated by molecular weight, production method, and biological activity. This guide examines the science behind the safety debate.

General information, not medical advice. Sea moss contains iodine. Ask your GP before use if you have a thyroid condition, take medication, or are pregnant or breastfeeding. Quality & Testing.

## Introduction: The category error behind the carrageenan scare If you have ever scanned an ingredient list for carrageenan and set the product back on the shelf, you are not alone. A decade of blog posts, Netflix documentaries, and petition campaigns have trained health-conscious consumers to treat carrageenan as a synonym for gut inflammation and cancer risk. The objection is familiar: "I avoid carrageenan in my almond milk why would I eat sea moss that is full of it?" The concern is understandable. But it rests on a single category error one that conflates two chemically distinct substances separated by an order-of-magnitude difference in molecular weight, radically different production methods, and divergent biological behaviour. Those two substances are **food-grade carrageenan** and **poligeenan**, and the failure to distinguish between them has distorted public understanding for over two decades. This article walks through the molecular weight boundary that separates them, the origin of the confusion in the scientific literature, the regulatory safety record across four independent agencies, and why whole-food sea moss cannot generate poligeenan under human digestive conditions. Every claim is cited to peer-reviewed literature or regulatory primary sources. ## The molecular weight boundary: Two substances, not one The single most important fact in this debate is a number: **molecular weight**. Food-grade carrageenan and poligeenan are defined, classified, and regulated based on where they sit relative to a molecular weight threshold. ### Defining the terms | Property | Food-grade carrageenan (CGN) | Poligeenan (PGN) | | --- | --- | --- | | Weight-average molecular weight | 200,000 800,000 Da (200 800 kDa) | 10,000 20,000 Da (10 20 kDa) | | Regulatory classification | Approved food additive (INS 407) | Not authorised for food use | | Production method | Alkaline extraction from red seaweed | Sustained acid hydrolysis at pH less than 1.3, temperatures above 80 degrees C, for multiple hours | | Primary use | Gelling, thickening, stabilising agent in food | Diagnostic medical imaging (barium enema suspensions) | | Biological behaviour | Resists upper GI digestion; fermented by colonic bacteria | Absorbed; associated with intestinal inflammation in animal models | > "CGN cannot be hydrolyzed to PGN in vivo." > McKim, Willoughby, Blakemore, & Weiner (2019), *Critical Reviews in Food Science and Nutrition* The United States Adopted Names Council assigned the name "poligeenan" specifically to the 10,000 20,000 Da polymer to end the historical practice of calling it "degraded carrageenan" a label that implied a continuum rather than a categorical distinction (McKim et al., 2019). ### Why the gap matters biologically The molecular weight difference is not merely taxonomic. It determines whether the molecule can cross the intestinal epithelial barrier: ``` Food-grade carrageenan Poligeenan 200 800 kDa 10 20 kDa | | v v Too large to cross Small enough to cross epithelial tight epithelial barrier and junctions; remains interact with mucosal in the GI lumen immune cells | | v v Fermented in colon Associated with by Bacteroidetes; inflammation in produces SCFAs animal models ``` Food-grade carrageenan, with its high molecular weight and protein-binding capacity, passes through the upper gastrointestinal tract largely intact. It is not significantly absorbed or metabolised (Weiner, 2014). Poligeenan, by contrast, is small enough to penetrate the mucosal barrier and has been associated with intestinal ulceration in preclinical animal models but it is never used in food and does not form under physiological conditions (McKim et al., 2019). ## How poligeenan is made: Conditions that do not exist in your stomach The conversion of carrageenan into poligeenan requires three simultaneous extremes: 1. **pH below 1.3** (concentrated acid, far below gastric pH) 2. **Temperature above 80 degrees C** (more than double core body temperature) 3. **Sustained exposure for multiple hours** (gastric transit averages 2 4 hours) ### The physiological impossibility The human stomach operates under fundamentally different conditions: | Parameter | Poligeenan production | Human stomach | | --- | --- | --- | | pH | Less than 1.0 1.3 | 1.5 3.5 (fasted); 4.5 6.7 (fed) | | Temperature | Above 80 degrees C | 37 degrees C | | Duration at extreme conditions | 4 6 hours sustained | 2 4 hours transit, non-sustained | | Acid concentration | 0.1 M sulfuric acid | Dilute hydrochloric acid | The gap between these conditions is not marginal it is categorical. At 37 degrees C and physiological pH, carrageenan retains its high molecular weight structure. McKim et al. (2019) confirmed that "the formation of poligeenan in the human gastrointestinal tract does not occur due to the lack of the pH and temperature conditions needed to produce these molecules." Furthermore, in vivo studies in rodents, dogs, and non-human primates have shown that ingested food-grade carrageenan is excreted quantitatively in the faeces without significant degradation by gastric acid or intestinal microflora (Weiner, 2014). > When consuming whole *Chondrus crispus* in gel form, the carrageenan remains embedded within the algal cell wall matrix, further protecting it from acid hydrolysis during the relatively brief gastric transit. ## The Tobacman controversy: How conflation distorted the literature ### The 2001 review that started the scare In 2001, Joanne Tobacman published a review in *Environmental Health Perspectives* titled "Review of harmful gastrointestinal effects of carrageenan in animal experiments." The paper examined existing preclinical research and concluded that "exposure to undegraded as well as to degraded carrageenan was associated with the occurrence of intestinal ulcerations and neoplasms" (Tobacman, 2001). This review became the foundational citation for anti-carrageenan advocacy. Health blogs, petition campaigns, and documentaries cited it as evidence that carrageenan the food additive in almond milk, ice cream, and infant formula caused cancer and gut damage. ### The critical flaw: nomenclature conflation The central problem with the Tobacman review, as identified by multiple subsequent analyses, is that it conflated experiments conducted with poligeenan (then still called "degraded carrageenan") with experiments conducted using food-grade carrageenan. The review argued that undegraded carrageenan could convert to degraded forms through "acid hydrolysis under conditions of normal digestion" a claim that subsequent in vivo molecular weight analyses have not supported (McKim et al., 2019; Weiner, 2014). McKim et al. (2019) catalogued the specific methodological issues: - [ ] Many cited studies used poligeenan (10 20 kDa) but were presented as evidence against food-grade carrageenan (200 800 kDa) - [ ] Dose levels in animal studies frequently exceeded plausible human dietary exposure by orders of magnitude - [ ] The review did not adequately account for interspecies differences in gastrointestinal physiology - [ ] Nomenclature confusion between "degraded carrageenan" and "carrageenan" persisted throughout ### Regulatory responses to the Tobacman claims Following Tobacman's 2008 petition to the FDA requesting removal of carrageenan from the food supply, the FDA reviewed the evidence and declined the petition, maintaining carrageenan's GRAS (Generally Recognised as Safe) status. This decision was consistent with independent evaluations by JECFA, EFSA, and FSANZ. ## The regulatory safety record: Four agencies, one conclusion Food-grade carrageenan has been reviewed by every major international food safety authority. The consistency of their conclusions is notable. ### JECFA (Joint FAO/WHO Expert Committee on Food Additives) JECFA has evaluated carrageenan safety in **1969, 2002, 2007, and 2014**. Across these evaluations, carrageenan has maintained an Acceptable Daily Intake (ADI) classified as "not specified" the highest safety designation, meaning no toxicological concern was identified at normal dietary exposure levels. In its 79th meeting (2014), JECFA concluded that carrageenan in infant formula at concentrations up to 1,000 mg per litre is not of concern (JECFA, 2014). ### EFSA (European Food Safety Authority) In its 2018 re-evaluation, the EFSA Panel on Food Additives examined the full toxicological profile of carrageenan (E 407). The Panel found: - No concern with respect to **carcinogenicity** - No concern with respect to **genotoxicity** - NOAEL (no-observed-adverse-effect level) of **3,394 3,867 mg/kg body weight per day** in subchronic studies - No adverse effects in chronic toxicity studies up to **7,500 mg/kg body weight per day** The Panel established a temporary group ADI of 75 mg/kg body weight per day pending further data refinement (Younes et al., 2018). ### FDA (United States Food and Drug Administration) The FDA lists carrageenan as an approved food additive and GRAS substance, authorised for use as a thickener, stabiliser, emulsifier, and texturiser. Following review of Tobacman's 2008 petition, the FDA reaffirmed this position. ### FSANZ (Food Standards Australia New Zealand) In Australia and New Zealand, carrageenan is permitted under **Standard 1.3.1** of the Food Standards Code, with permitted uses and restrictions detailed in **Schedule 15**. It is labelled as "vegetable gum (407)," "carrageenan gum," or "vegetable gum (carrageenan)" on Australian product labels (FSANZ, 2024). There is no numerical ADI restriction for the general population. ### Summary of regulatory positions | Authority | Year(s) reviewed | Conclusion | ADI | | --- | --- | --- | --- | | JECFA | 1969, 2002, 2007, 2014 | Safe; no concern at dietary exposure | Not specified (highest safety class) | | EFSA | 2018 | No carcinogenicity or genotoxicity concern | 75 mg/kg bw/day (temporary) | | FDA | Ongoing (GRAS since 1961) | Safe; petition to remove denied | Not specified | | FSANZ | Ongoing | Permitted under Standard 1.3.1, Schedule 15 | No numerical restriction | ## What happens to carrageenan in whole sea moss during digestion The carrageenan scare primarily targets the isolated food additive the purified powder added to processed products. But consumers of whole *Chondrus crispus* gel encounter carrageenan in a fundamentally different matrix: embedded within the algal cell wall alongside proteins, minerals, and other polysaccharides. ### Upper GI tract: Resistance to degradation Native kappa-carrageenan in whole sea moss resists human digestive enzymes. The human genome does not encode the carbohydrate-active enzymes (specifically kappa-carrageenases) needed to cleave the specific beta-1,4 and alpha-1,3 glycosidic linkages in the carrageenan backbone. As a result, carrageenan transits the stomach and small intestine intact, reaching the colon with its high molecular weight preserved (Weiner, 2014). ### Colonic fermentation: A prebiotic substrate In the colon, specific **Bacteroidetes** species notably *Bacteroides xylanisolvens* possess beta-carrageenase enzymes capable of cleaving carrageenan into oligosaccharides. This saccharolytic fermentation produces short-chain fatty acids (SCFAs), including acetic, propionic, and butyric acids (Li et al., 2014). Butyrate serves as the primary energy source for colonic epithelial cells and plays a role in maintaining the integrity of the colonic lining. This positions native carrageenan as a **prebiotic substrate** rather than an inflammatory agent a distinction that is lost when whole-food sea moss is conflated with isolated poligeenan. For a deeper analysis of sea moss prebiotic activity and the conditions under which it may cause bloating rather than benefit, see [Sea Moss and the Gut: Superfood Remedy or Bloating Catalyst?](/blogs/learn/benefits/sea-moss-gut-health). ### The whole-food matrix advantage ``` Whole Chondrus crispus gel | v Carrageenan embedded in cell wall + protein matrix | β”Œβ”€β”€β”€β”€β”΄β”€β”€β”€β”€β” v v Stomach Small intestine (pH 1.5-3.5, (pH 6-7, 37 deg C) 37 deg C) | | v v Intact Intact (no enzymes (no kappa- to cleave) carrageenase) | v Colon | v Bacteroidetes fermentation | v Short-chain fatty acids (butyrate, acetate, propionate) ``` ## Acknowledging the ongoing debate: Where legitimate caution remains Scientific integrity requires acknowledging that the carrageenan literature is not unanimously positive. While the poligeenan conflation accounts for much of the alarm, some researchers have raised questions about food-grade carrageenan that warrant continued investigation. ### Areas of legitimate research interest Borsani et al. (2021) published a review in *Nutrients* noting that a small randomised controlled trial found earlier relapse in ulcerative colitis patients receiving carrageenan capsules compared with placebo. The authors suggested that "low molecular weight CGN or degraded CGN may be the culprit of the adverse effects" acknowledging that the molecular weight variable remains central even within critical studies. However, this study used isolated carrageenan capsules at controlled doses, not whole-food sea moss gel. The distinction between isolated additive exposure and whole-food matrix consumption is clinically relevant and under-explored. ### Self-assessment: Should you be cautious about carrageenan? Use this checklist to determine whether the carrageenan question is relevant to your situation: - [ ] **I have diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis)** Discuss sea moss with your gastroenterologist before starting; limited evidence suggests caution with isolated carrageenan in active IBD - [ ] **I have suspected or confirmed SIBO** Carrageenan fermentation may worsen symptoms; see our [SIBO decision tree](/blogs/learn/science-safety/sibo-sea-moss-decision-tree) before starting - [ ] **I take anticoagulants (warfarin or similar)** Sea moss contains vitamin K, which interacts with blood thinners; consult your prescriber - [ ] **I have a thyroid condition or am pregnant** The iodine content of sea moss is the primary concern, not carrageenan; verify iodine per lot and consult your endocrinologist - [ ] **I am healthy and consuming whole-food sea moss gel at standard doses (1 2 tablespoons daily)** Current evidence from JECFA, EFSA, FDA, and FSANZ supports safety at normal dietary exposure levels If you ticked any of the first four items, seek practitioner guidance before regular consumption. ## Species honesty: Carrageenan type varies by species Not all "sea moss" contains the same carrageenan. The species you consume determines the type and proportion of carrageenan present: | Species | Primary carrageenan type | Notes | | --- | --- | --- | | *Chondrus crispus* (Irish moss) | Kappa and lambda | Wild-harvested North Atlantic; the traditional standard | | *Eucheuma cottonii* (tropical) | Kappa | Farm-cultivated; the most common commercial species | | *Gracilaria* spp. (tropical) | Produces agar, not carrageenan | Often sold as "sea moss" but taxonomically distinct | This matters because the prebiotic fermentation profile, gel-forming behaviour, and mineral content differ meaningfully across species. At SeaMossVibes, we source wild-harvested *Chondrus crispus* from Saint Lucia and verify species identity per batch. For a detailed comparison, see [Species Identification: Chondrus vs. Gracilaria](/blogs/learn/science-safety/species-identification-chondrus-vs-gracilaria). ## Mandatory disclosures **TGA disclaimer:** This article is educational and does not constitute medical advice. Sea moss products sold in Australia are not evaluated by the Therapeutic Goods Administration (TGA) for the treatment, cure, or prevention of any disease. **Iodine safety:** Sea moss is a potent iodine accumulator. The tolerable upper intake level for iodine in healthy adults is 1,100 mcg per day. Some batches of *Chondrus crispus* may exceed this threshold in a single serving. Always check the iodine quantification (mcg/g) on your supplier's Certificate of Analysis (COA) before dosing. **Practitioner consultation:** If you have a thyroid condition, cardiovascular disease, are pregnant or breastfeeding, or take anticoagulant medications, consult your healthcare practitioner before consuming sea moss. **Heavy metal sourcing:** As a marine bioaccumulator, sea moss concentrates heavy metals from its environment. Consumer safety depends on per-lot ICP-MS testing for total heavy metals and HPLC-ICP-MS arsenic speciation to distinguish toxic inorganic arsenic from benign organic arsenosugars. Request batch-specific COAs from your supplier. **Species honesty:** The commercial label "sea moss" encompasses multiple genera with distinct biochemical profiles. *Chondrus crispus*, *Eucheuma*, and *Gracilaria* are not interchangeable. Confirm species identification before assuming any nutritional or safety claim applies to your product. **Allergy disclosure:** Carrageenan-containing products may not be suitable for individuals with known hypersensitivity to red algae or sulphated polysaccharides. Discontinue use and consult a healthcare professional if you experience adverse reactions. ## Conclusion The carrageenan scare is, at its core, a nomenclature problem that escalated into a public health misunderstanding. Food-grade carrageenan and poligeenan differ by an order of magnitude in molecular weight (200 800 kDa versus 10 20 kDa), require entirely different production conditions, and exhibit fundamentally different biological behaviour. Poligeenan is produced only under extreme laboratory conditions pH below 1.3, temperatures above 80 degrees C, sustained for hours conditions that do not exist in the human gastrointestinal tract at 37 degrees C. Four independent regulatory agencies JECFA, EFSA, FDA, and FSANZ have reviewed the evidence and concluded that food-grade carrageenan is safe at normal dietary exposure. The Tobacman (2001) review that catalysed the scare has been specifically challenged for conflating poligeenan experiments with food-grade carrageenan evidence. For consumers of whole-food *Chondrus crispus* gel, native kappa-carrageenan remains embedded in the algal cell wall matrix, resists upper GI degradation, and is fermented in the colon by Bacteroidetes to produce beneficial short-chain fatty acids. This is the opposite of the inflammatory narrative but it requires species verification, batch testing, and practitioner oversight for individuals with IBD, thyroid conditions, or relevant medication regimens. ## Next step [Take the Vitality Assessment](/vitality/assessment) to determine whether whole-food sea moss gel suits your health profile including gut status, thyroid baseline, and medication interactions before you start. ## References - Borsani, B., De Santis, R., Perico, V., Penagini, F., Pendezza, E., Dilillo, D., Bosetti, A., Zuccotti, G. V., & D'Auria, E. (2021). The role of carrageenan in inflammatory bowel diseases and allergic reactions: Where do we stand? *Nutrients*, 13(10), 3402. https://pmc.ncbi.nlm.nih.gov/articles/PMC8539934/ - Food Standards Australia New Zealand. (2024). How FSANZ ensures the safety of food additives. https://www.foodstandards.gov.au/consumer/additives/additivecontrol - Joint FAO/WHO Expert Committee on Food Additives. (2014). Safety evaluation of certain food additives: Seventy-ninth meeting. *WHO Technical Report Series*, No. 990. https://inchem.org/documents/jecfa/jecmono/v990je01.pdf - Li, L., Ni, R., Shao, Y., & Mao, S. (2014). Carrageenan and its applications in drug delivery. *Carbohydrate Polymers*, 103, 1 11. - McKim, J. M., Willoughby, J. A., Sr., Blakemore, W. R., & Weiner, M. L. (2019). Clarifying the confusion between poligeenan, degraded carrageenan, and carrageenan: A review of the chemistry, nomenclature, and in vivo toxicology by the oral route. *Critical Reviews in Food Science and Nutrition*, 59(19), 3054 3073. https://doi.org/10.1080/10408398.2018.1481822 - Tobacman, J. K. (2001). Review of harmful gastrointestinal effects of carrageenan in animal experiments. *Environmental Health Perspectives*, 109(10), 983 994. https://pmc.ncbi.nlm.nih.gov/articles/PMC1242073 - Weiner, M. L. (2014). Food additive carrageenan: Part II: A critical review of carrageenan in vivo safety studies. *Critical Reviews in Toxicology*, 44(3), 244 269. https://doi.org/10.3109/10408444.2013.861798 - Weiner, M. L., & McKim, J. M., Jr. (2019). Comment on "Revisiting the carrageenan controversy: Do we really understand the digestive fate and safety of carrageenan in our foods?" *Food & Function*, 10, 1760 1762. https://doi.org/10.1039/C8FO01282B - Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Filipic, M., Frutos, M. J., Galtier, P., Gott, D., Gundert-Remy, U., Kuhnle, G. G., LambrΓ©, C., Leblanc, J.-C., Lillegaard, I. T., Moldeus, P., Mortensen, A., Oskarsson, A., Stankovic, I., Waalkens-Berendsen, I., Woutersen, R. A., ... Wright, M. (2018). Re-evaluation of carrageenan (E 407) and processed Eucheuma seaweed (E 407a) as food additives. *EFSA Journal*, 16(4), e05238. https://doi.org/10.2903/j.efsa.2018.5238

Ready to start?

Turn what you learned into a daily ritual

Explore formats and product details, then check the physical label before use.

Explore products β†’

Listed ingredients Β· Storage guidance

Read next

  • Listed product details
  • Available report scope
  • Secure checkout
  • Shipping policy available